Sling Therapeutics, Inc.

Linsitinib Shows Promise in Reducing Proptosis in Thyroid Eye Disease

4 months ago

• Linsitinib, an oral small molecule, significantly reduced proptosis in patients with active, moderate to severe thyroid eye disease (TED) in a Phase 2b/3 trial. • The LIDS trial met its primary endpoint, demonstrating a statistically significant proptosis responder rate of 52% (p = 0.01) at Week 24 with the 150mg BID dose. • Linsitinib exhibited a favorable safety profile, with no drug-related hearing impairment, tinnitus, or menstrual cycle changes reported in the trial. • Sling Therapeutics plans to initiate a confirmatory Phase 3 trial in 2025, aiming to provide a convenient oral treatment option for TED patients.

Focused Ultrasound Shows Promise in Alzheimer's Treatment

4 months ago

• A clinical trial using focused ultrasound to treat Alzheimer’s disease has shown promising results, marking a potential new direction in treating this debilitating condition. • The study, published in the Journal of Neurosurgery, highlights the noninvasive nature of focused ultrasound as a key advantage in Alzheimer's treatment. • Researchers are optimistic about the potential of this approach to offer a new therapeutic avenue for patients suffering from Alzheimer's disease. • Further research is needed to fully understand the long-term effects and optimal use of focused ultrasound in Alzheimer's treatment.

Sling Therapeutics Appoints Andrew Guggenhime to Board as Linsitinib Advances in Phase 2b for TED

5 months ago

• Sling Therapeutics appointed Andrew Guggenhime to its Board of Directors, leveraging his extensive biopharma experience to advance clinical programs. • Guggenhime's financial expertise will support Sling as it anticipates key milestones for linsitinib, an oral treatment for thyroid eye disease (TED). • Linsitinib is currently in a Phase 2b clinical trial and aims to offer a more convenient, patient-centric option for TED, addressing an underserved market. • TED affects approximately 70,000 people in the U.S. annually, and linsitinib targets the IGF-1R signaling pathway implicated in the disease.

Sling Therapeutics Initiates Enrollment in Phase 2b LIDS Clinical Trial for Thyroid Eye Disease

3 years ago

Sling Therapeutics has begun enrolling participants for a global Phase 2b LIDS clinical trial to evaluate the safety, pharmacokinetics, and efficacy of linsitinib, an oral IGF-1R inhibitor, in treating active, moderate to severe thyroid eye disease (TED). This trial marks a significant step towards reducing the treatment burden for TED patients.

Sling Therapeutics Launches with $35M Series A Financing to Develop Oral Small Molecule for Thyroid Eye Disease

3 years ago

Sling Therapeutics, Inc. has officially launched with a $35M Series A financing led by TPG's The Rise Fund, aiming to develop linsitinib, an oral small molecule for treating Thyroid Eye Disease (TED). The company has received FDA IND clearance and is preparing to initiate a Phase 2b clinical trial. Linsitinib, designed to inhibit the IGF-1R signaling pathway, offers a potential convenient oral treatment option for TED patients, aiming to reduce the treatment burden significantly.